Current Takeaway
Severe and very severe ME/CFS patients occupy a blind spot in both clinical practice and research: they are too ill to travel to specialist centres, routinely excluded from trials, and face a medical landscape that has rarely acknowledged their physiological complexity. Emerging work is beginning to close that gap from several directions at once — inpatient care models focused on PEM minimisation, structured outreach protocols that bring diagnostics to housebound patients, risk-stratification tools for identifying who deteriorates earliest after post-viral illness, and the first systematic perioperative safety data for this population.
The evidence base is still early. Most published work is retrospective, single-centre, or protocol-only, with small samples and no controlled comparisons between care models. What the literature consistently establishes is that severe ME/CFS is a multisystem physiological crisis rather than a severity variant of ordinary fatigue, that standard clinical environments can cause harm through overstimulation and enforced exertion, and that meaningful diagnostic and care work is possible without requiring patients to leave their homes — provided the assessment is carefully staged and PEM risk is monitored at each step.
Why This Matters
For carers and families managing a severely affected person, the practical absence of evidence-based care protocols has long been one of the most disabling aspects of the disease system. Clinicians encountering these patients in surgical, emergency, or general medical settings have had almost no data to guide management. Researchers wanting to study the most affected patients have lacked validated methods for including them safely.
The sources tracked here address each of those gaps directly. Inpatient outcome data from Norway show what happens when a genuinely adapted environment is offered. Outreach diagnostic protocols from Germany show what careful home-based assessment can look like. Perioperative data from a German tertiary anaesthesia centre show where surgical risk is concentrated. Together they sketch the beginnings of a clinical and research infrastructure for the population that has so far been most invisible.
State of Evidence
- Established: Severe and very severe ME/CFS patients are systematically underrepresented in research because standard trial participation requires travel and exertion that can cause lasting deterioration. This exclusion produces a self-reinforcing evidence gap at the most severe end of the disease spectrum.
- Plausible but early: A dedicated inpatient care environment that prioritises PEM avoidance and sensory adaptation may produce measurable clinical improvement in some severely affected patients, particularly those with shorter illness duration. Staged outreach diagnostics are feasible in housebound patients without triggering uniform deterioration. Acute-phase symptom complexity in young people predicts severe long-term outcome.
- Not established: Which specific components of inpatient or outreach care drive improvement. Whether early risk stratification in children and young adults changes long-term outcomes. The full perioperative risk profile in ME/CFS, particularly delayed PEM following general anaesthesia.
- Key limitations: All current inpatient and outreach outcome data come from single centres with fewer than 25 patients. The paediatric risk-stratification study is monocentric and used a registry design. The perioperative study has 15 ME/CFS patients matched to 15 controls. Protocol publications like ACHTSAM have not yet reported outcome data. Evidence of what does not work — high-stimulation environments, mandatory physical therapy, and standard surgical pain protocols — is largely derived from adverse patient experience rather than controlled comparison.
Timeline
2025-10-01 - Norwegian inpatient unit reports 50% improvement rate in severely ill patients
Saugstad et al. published a retrospective review of the first three years of the Røysumtunet ME unit in Norway, the country’s first dedicated inpatient facility for severely and very severely ill ME/CFS patients. Twenty-four patients who had stayed for at least three months between June 2021 and June 2024 were included; all met NICE severity criteria for severe or very severe disease. Half of the patients showed measurable improvement during their stay, with seven (29%) moving up at least one NICE severity level and a further five showing within-level gains such as improved sensory tolerance or slightly expanded daily activity. Improvement was strongly associated with shorter illness duration — improvers had been ill for a mean of 2.3 years versus 6.7 years for non-improvers — which raises the question of whether early access to adapted care might prevent some of the accumulating severity seen in longer-duration patients. The unit also offered an optional multi-supplement and low-dose medication programme including thiamine, NADH, CoQ10, vitamin B12, low-dose naltrexone, and low-dose aripiprazole, but the study design does not allow any conclusions about what those contributed. The main lesson the authors draw is that a safe, low-stimulation environment where PEM is actively managed appears to be a meaningful intervention in its own right.
Sources:
2025-12-02 - Acute-phase symptom load predicts severe long-term outcome in children and young adults
A German registry study at the Munich Chronic Fatigue Center for Young People enrolled 120 participants aged 7–25 with post-COVID condition and tracked symptom severity from acute infection through the chronic phase using validated scales and a purpose-built questionnaire. Twenty-four percent of participants met ME/CFS criteria, and all of those fell into the severest clinical group. The strongest predictors of severe long-term illness were a high total symptom count during the acute infection (twelve or more symptoms), female sex, early orthostatic intolerance, and concentration difficulties — all identifiable without specialist testing. A threshold of twelve or more acute symptoms showed high specificity for the group likely to need intensive long-term monitoring. The implication is that risk stratification for the most severe outcomes may be possible at the point of acute illness, potentially allowing earlier specialist referral before the window of shorter illness duration has passed. The study is monocentric, cannot demonstrate that earlier referral changes outcomes, and uses a novel questionnaire not yet validated in independent cohorts.
Sources:
2026-01-19 - Literature review maps the clinical profile and systemic burden of severe ME/CFS
Vink and Vink-Niese published a comprehensive review in the Journal of Clinical Medicine documenting the clinical characteristics of severe and very severe ME/CFS, drawing on biomedical literature and international patient surveys. The review describes extreme sensory hypersensitivity in which even a soft voice or low-level light can trigger multi-day relapses, the prevalence of life-threatening malnutrition requiring tube feeding in a subset of very severely affected patients, and a high frequency of medical misattribution that delays appropriate care. The authors note that this subgroup is largely invisible in research — approximately 0.5% of ME/CFS publications focus on severe cases despite those patients bearing some of the greatest disease burden — and that two-day CPET and other physiologic tools can objectively characterise functional collapse even when standard resting assessments appear unremarkable. The review does not add new primary data, but it consolidates the clinical picture needed to understand why standard care environments cause harm and why specialist inpatient and outreach approaches are a prerequisite rather than a luxury.
Sources:
2026-03-06 - ACHTSAM protocol establishes framework for home-visit diagnostics in housebound ME/CFS
Fricke et al. published the protocol for ACHTSAM, a prospective non-interventional pilot study at the University Medical Center Freiburg designed to test whether a structured sequence of home-based diagnostic assessments can be completed by severely and very severely ill ME/CFS patients without triggering clinically significant deterioration. The two-phase design begins with remote screening using validated questionnaires, then moves to staged home visits by a medical team. Planned assessments include physiological monitoring (endothelial function testing), cognitive evaluations, and biological sampling. The primary feasibility endpoint is the proportion of assessment modules completed by patients with Bell scores of 30 or below without triggering premature termination. The protocol explicitly acknowledges the difficulty of attributing delayed PEM to individual tests in a multisystem assessment, and involved patients and carers in its design to ensure safety and relevance. No outcome data have been published yet, so the value of the protocol is currently in establishing the methodology rather than in clinical findings.
Sources:
2026-04-07 - First matched-pair study quantifies perioperative risk in ME/CFS
Steinkirchner et al. published a retrospective matched-pair analysis at the University Hospital Regensburg comparing 15 ME/CFS patients with 15 age-, sex-, and procedure-matched controls undergoing general anaesthesia between 2015 and 2026. Intraoperative haemodynamics were lower in ME/CFS patients — minimum heart rate and minimum systolic blood pressure were both reduced — but remained within clinically safe limits throughout the procedures. The difference that did reach clinical significance was postoperative pain: ME/CFS patients reported maximum pain scores of 5.0 versus 1.0 in controls, and 80% required opioid rescue analgesia compared with 33% of controls. The study was not designed to capture delayed post-exertional deterioration in the days and weeks following surgery, which is the outcome most relevant to ME/CFS-specific surgical risk. That gap remains unaddressed in the published literature. The practical implication of what was measured is that standard surgical pain protocols are likely insufficient for this population and that anaesthesiologists and surgical teams need disease-specific preparation before operating on ME/CFS patients.
Sources:
2026-06-01 - First German-language transdisciplinary care guide published for severe ME/CFS home care
A transdisciplinary Austrian expert group—including nursing scientists, physiotherapists, general practitioners, public health researchers, and patient/family-caregiver representatives—published the first German-language consensus practice guide for home-based care of severely affected ME/CFS patients in Wiener Medizinische Wochenschrift. The guide addresses the tension that care-dependent patients with severe ME/CFS require substantial nursing support, yet the defining feature of their illness (PEM) means that any care activity can trigger disproportionate deterioration if individual exertion thresholds are exceeded. It outlines PEM-aware adaptations for daily care activities (nutrition, hygiene, positioning, and communication), symptom-specific management, home-visit planning, and the potential application of palliative care principles. The statement warns against standard rehabilitation or graded-activity approaches and highlights the reliance on family caregivers. As an expert consensus statement rather than a randomized controlled trial, it represents clinical consensus and patient/caregiver experience rather than high-level experimental efficacy evidence.
Sources:
Open Questions
- Whether the improvement signal from the Røysumtunet unit can be replicated in a multicentre setting, and what the active ingredients of adapted inpatient care are.
- Whether ACHTSAM’s outreach diagnostic framework will prove feasible and PEM-safe when applied across the planned patient range, and whether the physiological measurements taken at home yield interpretable data.
- What happens to ME/CFS patients in the days and weeks after surgery — the perioperative PEM window that the current retrospective data cannot capture.
- Whether the acute-phase risk factors identified in children and young adults with post-COVID condition apply to ME/CFS arising after other viral triggers or in adult-onset cases.